II期子宫内膜癌的结局:UPMC希尔曼癌症中心经验
该回顾性分析纳入1990-2013年UPMC希尔曼癌症中心110例手术分期的FIGO II期子宫内膜癌患者,中位随访64.6个月,5年局部区域控制率、远处转移率、无病生存率和总生存率分别为94.9%、85.1%、67.9%和75.0%。多数患者(84.5%)接受体外放疗±近距离放疗,13.6%仅接受近距离放疗,远处转移仍是主要失败模式。
要点
- 110例现代定义(宫颈间质浸润)FIGO II期子宫内膜癌患者,5年局部区域控制率94.9%。
- 5年远处转移率、无病生存率和总生存率分别为85.1%、67.9%和75.0%。
- 盆腔淋巴结清扫是唯一与局部区域控制相关的因素,远处转移仍为主要失败模式。
核心结论
- 这是现代定义II期子宫内膜癌最大的单机构研究,证实手术后辅助治疗可获得高的盆腔疾病控制率。
- 多数患者接受辅助放疗,主要失败模式仍为远处转移,但绝对数量低。
研究设计与样本
- 回顾性分析,纳入1990-2013年UPMC希尔曼癌症中心110例手术分期的FIGO II期子宫内膜癌患者。
- 采用对数秩检验分析局部区域控制、远处转移、无病生存和总生存的相关因素。
主要发现
- 中位随访64.6个月,5年局部区域控制率、远处转移率、无病生存率和总生存率分别为94.9%、85.1%、67.9%和75.0%。
- 84.5%的患者接受体外放疗±近距离放疗,13.6%仅接受近距离放疗。
- 5例局部区域失败,盆腔淋巴结清扫是唯一预测局部区域控制的因素。
- 与远处转移相关的因素包括年龄、淋巴血管间隙浸润、肌层浸润深度和接受化疗。
- 预测无病生存和总生存的因素包括年龄、分级、不良组织学、淋巴血管间隙浸润、肌层浸润深度和接受化疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies of stage II endometrial cancer have included cancers with cervical glandular involvement, a factor no longer associated with risk of recurrence. In order to better assess relapse patterns and the impact of adjuvant therapy, a retrospective analysis was conducted for patients with modern stage II endometrial cancer, defined as cervical stromal invasion. MATERIALS AND METHODS: Patients diagnosed with surgically staged FIGO stage II endometrial cancer at the UPMC Hillman Cancer Center from 1990-2013 were reviewed. Factors associated with rates of locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS) were analyzed using the log rank test. RESULTS: 110 patients with FIGO stage II disease were identified. Most (84.5%) received EBRT±BT, with 13.6% receiving BT alone. With a median follow-up of 64.6months, the 5-year actuarial rates of LRC, DM, DFS, and OS were 94.9%, 85.1%, 67.9%, and 75.0%, respectively. With 5 locoregional failures, the only factor predictive of LRC was pelvic lymph node dissection. Characteristics associated with DM included age, LVSI, depth of myometrial invasion, and receipt of chemotherapy. Factors predictive of both DFS and OS were age, grade, adverse histology, LVSI, depth of myometrial invasion, and receipt of chemotherapy. CONCLUSIONS: This represents the largest single-institution study for modern stage II endometrial cancer, confirming high rates of pelvic disease control after surgery and adjuvant therapy. With most patients receiving adjuvant radiotherapy, the predominant mode of failure, albeit low in absolute number, remains distant metastases.
引用
- Chen KS, Berhane H, Gill BS, et al. Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience. Gynecol Oncol. 2017. PMID: 28866431. doi:10.1016/j.ygyno.2017.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。